Mesoblast (ASX:MSB) Common Stock: A$2,286.78 Mil (As of Dec. 2025)


ASX:MSB Mesoblast Ltd ASX:MSB
51 GF Score
Price A$1.95
! 4 Warning Signs
View Full Analysis

What is Mesoblast Common Stock?

Mesoblast ASX:MSB +3.45% 51 Common Stock is A$2,286.78 Mil as of Dec. 2025. GuruFocus rates ASX:MSB with a GF Score™ of 51/100. The stock has 4 warning signs investors should review.

Mesoblast's quarterly common stock declined from Jun. 2025 (A$2,317.59 Mil) to Sep. 2025 (A$0.00 Mil) but then increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$2,286.78 Mil).

Mesoblast's annual common stock increased from Jun. 2023 (A$1,861.19 Mil) to Jun. 2024 (A$1,974.08 Mil) and increased from Jun. 2024 (A$1,974.08 Mil) to Jun. 2025 (A$2,317.59 Mil).

Mesoblast Common Stock Historical Data

* Premium members only.

The historical data trend for Mesoblast's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Common Stock Chart

Mesoblast Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,521.40 1,658.24 1,861.19 1,974.08 2,317.59

Mesoblast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2,317.59 0.00 2,286.78 0.00
ASX:MSB
51GF Score
Mesoblast Ltd ASX:MSB
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$2,286.78 Mil mean?
Mesoblast (ASX:MSB) has a Common Stock of A$2,286.78 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Mesoblast and its competitors.
Is Mesoblast's Common Stock too high?
Mesoblast's current Common Stock is A$2,286.78 Mil. Overall, Mesoblast has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Common Stock compare to VRTX and REGN?
Mesoblast's Common Stock of A$2,286.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Mesoblast and its competitors. Mesoblast's current Common Stock is A$2,286.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Common Stock of A$2,286.78 Mil. The current Common Stock is A$2,286.78 Mil. Mesoblast's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Common Stock is A$2,286.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
51GF Score

Get the complete analysis for ASX:MSB

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.95
Price